Tag: Biotech and Pharma

Nektar Therapeutics (NASDAQ:NKTR) stock surged 140% after the company announced its experimental drug rezpegaldesleukin met primary and key secondary endpoints in a Phase 2b study for moderate-to-severe atopic dermatitis.

Shares in Novo Nordisk (NYSE:NVO) fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema fuelled investor concerns about its competitiveness against rival Eli Lilly (NYSE:LLY)’s pipeline.

Hims & Hers Health (NYSE:HIMS) stock plunged 20% after pharmaceutical giant Novo Nordisk (NYSE:NVO) announced it would terminate its collaboration with the telehealth company over the sale of weight loss drugs.

Shares of AstraZeneca (ST:AZN) and GlaxoSmithKline (LON:GSK) fell on Wednesday after U.S. President Donald Trump said tariffs on imported drugs could be imposed “very soon.”

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, to boost its pipeline of experimental medicines beyond its blockbuster weight-loss and diabetes drugs.

Dyne Therapeutics, Inc. (Nasdaq:DYN) stock fell 23% after the company announced an updated plan for obtaining U.S. Accelerated Approval for DYNE-101 in myotonic dystrophy type 1 (DM1) following a Type C meeting with the FDA.

Eli Lilly announced Monday that the highest doses of its flagship weight-loss treatment, Zepbound, will now be available in single-dose vials at a fixed monthly price of $499 through its direct-to-consumer platform LillyDirect.

BMO Capital and Piper Sandler downgraded Sarepta Therapeutics (NASDAQ:SRPT) after the company reported a second death linked to its gene therapy Elevidys in a non-ambulatory Duchenne muscular dystrophy (DMD) patient.

Merck announces that the US FDA has approved Keytruda (pembrolizumab) for the treatment of adult patients with locally advanced head and neck squamous cell carcinoma (HNSCC) that is resectable and PD-L1-expressing.

The U.S. Food and Drug Administration on Monday approved Merck (NSE:PROR)’s preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the company said.

The European Medicines Agency’s safety committee has concluded that the use of Novo Nordisk’s (NOVOb.CO), popular weight-loss drug Wegovy and its treatments for type 2 diabetes may cause rare occurrences of a potentially dangerous eye condition.

Hims & Hers Health announced Tuesday it will acquire European telehealth platform Zava in its push to expand globally.

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use for young people with obesity, new data shared with Reuters shows.

Moderna (NASDAQ:MRNA) saw its shares rose nearly 5% in premarket trading Monday after the U.S. Food and Drug Administration (FDA) has approved the drugmaker’s next-generation COVID-19 vaccine, mNEXSPIKE, for adults 65 and older, as well as individuals aged 12 to 64 with at least one underlying condition that increases their risk of severe illness.

Bristol Myers Squibb has signed a partnership worth up to $11bn to develop a BioNTech cancer drug that has the potential to beat the world’s bestselling medicine Keytruda.

The U.S. Food and Drug Administration has approved British drugmaker GSK’s (GSK.L), asthma drug to treat some patients with a chronic lung disease commonly known as “smoker’s lung”, the company said on Thursday.

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday.

Telehealth company Doximity’s quarterly earnings beat wasn’t enough to offset investors’ disappointment around its guidance for the coming fiscal year.

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Αύξηση κατά 32,4% παρουσιάζουν τα συνολικά κέρδη προ φόρων, τόκων και αποσβέσεων (EBITDA) του Ομίλου Lavipharm για το Α’ τρίμηνο του 2025, τα οποία διαμορφώθηκαν σε 3,77 εκατ. ευρώ έναντι 2,85 εκατ. κατά το αντίστοιχο διάστημα του προηγούμενου έτους.